Everything below concerns actin binding. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-03-22. Where a claim depends on a specific study, the study is described rather than over-claimed.
Regulatory status differs by country, but TB-500 is not an approved pharmaceutical in major jurisdictions. It is commonly sold as a research chemical for laboratory use, which places responsibility for identity and purity on the supplier and the laboratory. Published human data are limited, and most reports involve preclinical models or cell culture. Questions about whether the fragment mimics all actions of thymosin beta-4, and under which conditions, remain open. Independent verification of any material is therefore a practical requirement in research settings.
TB-500 is a synthetic heptapeptide with the sequence Ac-LKKTETQ. It corresponds to a short N-terminal region of thymosin beta-4, a 43-amino-acid protein found in many cell types. The fragment contains an actin-binding motif, which is one reason it appears in laboratory studies of cell migration and cytoskeletal dynamics. TB-500 is not the full-length protein and is produced as a research chemical rather than an approved therapeutic agent. Its molecular weight is approximately 889 Da.
Several names appear in scientific and commercial contexts for this peptide. The label TB-500 is informal and does not follow standard biochemical nomenclature. Research articles more often describe the compound as a thymosin beta-4 fragment, Tβ4 fragment, or by its sequence Ac-LKKTETQ. Confusing TB-500 with full-length thymosin beta-4 can lead to incorrect assumptions about activity because the fragment lacks the remaining residues of the parent protein. The relationship between fragment and parent protein remains an active area of study.
Published work involving this sequence spans actin-binding assays, cell-migration studies, wound-healing models, and cardiovascular or musculoskeletal experiments. Much of the biological rationale derives from in vitro systems and animal models, and the number of controlled human studies is small. Reported outcomes vary across preparations, doses, and routes, which complicates comparison between studies. Reviews generally describe the evidence base as preliminary rather than settled. Mechanistic explanations are often proposed by analogy to the parent protein rather than demonstrated directly.
TB-500 is a synthetic seven-amino-acid peptide with the sequence LKKTETQ, corresponding to residues 17 through 23 of the protein thymosin beta-4. The N-terminus is typically acetylated in the described form, giving a monoisotopic mass near 888.5 Da and an average mass of about 889 Da. The designation TB-500 is a catalogue label rather than a formal chemical name, and the same sequence appears in the literature under several alternative abbreviations. It is handled as a research reagent rather than a pharmaceutical product.
Thymosin beta-4 is a 43-residue actin-binding protein found in most mammalian cell types, where it participates in cytoskeletal regulation and cell migration. TB-500 represents only a short fragment of that protein and does not include the remaining residues. Whether the isolated fragment reproduces the full range of activities reported for the intact protein remains an open question. Researchers commonly treat the two as related but distinct entities when comparing results.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C38H68N10O14 | Calculated for the acetylated heptapeptide |
| Molecular weight | ~889 Da | Monoisotopic mass approximately 889.0 Da |
| Amino acid sequence | Ac-LKKTETQ | N-terminal acetylated seven-residue peptide |
| Appearance | White to off-white powder | Typically supplied as a lyophilized solid |
| Solubility class | Water-soluble | Peptides of this size generally dissolve in aqueous media |
Proposed activity centers on actin sequestration and on the movement of cells during repair processes. In cell culture and animal models, the fragment has been associated with migration, tube formation, and tissue remodeling. These observations are frequently described as preliminary, because most published work uses rodent or in vitro systems rather than controlled human trials. Whether the short fragment reproduces the effects of the full protein remains an open question, and the relationship between dose, route, and measured outcome is not well characterized.
The compound circulates in the literature as a research reagent rather than an approved therapeutic. Regulatory agencies in several countries have not authorized it for medical use, and sporting bodies list related thymosin beta-4 peptides among prohibited substances. Suppliers typically market it with a purity figure and a certificate of analysis, while peer-reviewed clinical reports remain sparse. Discussions therefore often separate laboratory findings from anecdotal reports, and reviewers tend to note the small size and methodological limits of the available studies.
TB-500 refers to a synthetic peptide fragment derived from the actin-binding region of thymosin beta-4, a protein present in most mammalian cells. The full protein contains forty-three amino acids, while the commonly sold fragment is a much shorter acetylated sequence, often cited as LKKTETQ. The fragment retains part of the actin-binding motif but lacks the remainder of the parent protein. Material sold under this name is usually lyophilized powder intended for laboratory research, and it is not a finished pharmaceutical product.
The designation TB-500 circulates in laboratory and catalog contexts without a single agreed definition. Most product listings apply it to an N-terminally acetylated seven-residue fragment of thymosin beta-4, while other listings attach the same label to the full 43-residue protein. Because the term is commercial rather than systematic, two entries bearing identical names may describe different molecules. Any documentation should therefore state which sequence a given sample is claimed to contain.
The fragment most often associated with the name carries the sequence Ac-LKKTETQ, matching residues 17 through 23 of thymosin beta-4. That region holds the actin-binding motif responsible for much of the parent protein's biochemical activity. Apart from N-terminal acetylation the peptide is unmodified and contains no disulfide bonds, so it shows little ordered secondary structure in solution. Full-length thymosin beta-4 is instead a 43-residue polypeptide of roughly 4.9 kDa found widely across mammalian cell types.
TB-500 is a synthetic seven-residue peptide whose sequence, LKKTETQ, matches the N-terminal actin-binding region of thymosin beta-4. It is usually supplied in an N-terminally acetylated form, a modification that blocks the free amino terminus and can influence behavior in solution. In the research literature the same sequence appears under several names, including thymosin beta-4 fragment and shortened thymosin beta-4. Because it is a short peptide rather than the full 43-residue parent protein, its measured properties differ from those reported for thymosin beta-4 as a whole, and the two are not interchangeable in experimental design.
Thymosin beta-4 itself is a small, widely expressed protein that sequesters monomeric actin and participates in cell migration, angiogenesis, and tissue repair. Researchers have examined the shortened fragment as a possible mimic of some of these activities, reasoning that the actin-binding motif lies within the first few residues. Binding to monomeric actin has been observed in cell-free systems. Whether the fragment reproduces the broader effects of the full protein in living tissue remains an open question, and findings from animal models are frequently cited without a clear bridge to human physiology.
Discussion of TB-500 appears in several distinct literatures that rarely cite one another. Peer-reviewed studies usually describe in vitro assays or small animal experiments and are cautious about extrapolation. Veterinary and sports communities circulate anecdotal reports with limited methodological detail. Commercial listings add a third layer, often using the name interchangeably with thymosin beta-4 even though the two molecules differ in size and sequence. Regulatory status varies by country, and the compound is not a licensed medicine in most jurisdictions, so readers comparing sources should check which molecule and which purity each source actually describes.
Thymosin beta-4 contains 43 amino acids and has a reported molecular mass near 4963 Da. The short fragment most often associated with the TB-500 label, an acetylated chain beginning LKKTETQ, has a reported mass near 889 Da, so the two are easily separated in analytical work. Mass spectrometry and amino acid analysis can confirm which material is present in a given sample. Statements treating TB-500 and thymosin beta-4 as interchangeable are therefore imprecise, even though the two appear together in much of the same literature.
Interest in the compound comes largely from studies of the parent protein, which participates in actin sequestration, cell migration and tissue repair processes. Whether a short fragment reproduces those activities is a separate question that remains open in the published record. Many summaries describe mechanisms by analogy to thymosin beta-4 rather than from direct measurements on the fragment. Claims about activity should be treated as provisional unless a cited study specifies the exact peptide, its purity and the assay used.
== Efforts to characterize all human cell types == Several efforts have been made to make a list or a map of all human cells. One of the largest and most recent is the HuBMAP (Human BioMolecular Atlas Program). The HuBMAP project has organized 1551 different samples in 17 collections, each dedicated to a different system. However, this project still only mapped about 31 of the human body's 70 organs. Their datasets and visualisations place great emphasis on biomarkers and location in the body, but less on cell development and how cells can change over time. Usually specific surface proteins are used to identify cells, and based on this they are put into different categories. Another major effort to make an overview of these proteins that allows us to observe cell types is the Human Protein Atlas. A similar project, the Human Brain Project has also attempted to map the human brain, although much of the publicly accessible model does not have cellular resolution.
== Distribution == In humans, sarcosine is found at relatively low concentrations in the extracellular compartment, mitochondria, and peroxisomes. Tissues with measurable sarcosine concentrations include skeletal muscle and the prostate gland. Its cellular levels are tightly regulated by the balance between GNMT-mediated synthesis and SARDH/PIPOX-mediated catabolism.
=== 19th century === Apparently unaware of Smeaton's work, the same principle was identified by Frenchman Louis Vicat in the first decade of the nineteenth century. Vicat went on to devise a method of combining chalk and clay into an intimate mixture, and, burning this, produced an "artificial cement" in 1817 considered the "principal forerunner" of Portland cement and "...Edgar Dobbs of Southwark patented a cement of this kind in 1811." In Russia, Egor Cheliev created a new binder by mixing lime and clay. His results were published in 1822 in his book A Treatise on the Art to Prepare a Good Mortar published in St. Petersburg. A few years later in 1825, he published another book, which described various methods of making cement and concrete, and the benefits of cement in the construction of buildings and embankments.
== Clinical significance == MetO increases with age in body tissues, which is believed by some to contribute to biological ageing. Moreover, levels of methionine sulfoxide reductase A (MsrA) decline in aging tissues in mice and in association with age-related disease in humans. There is thus a rationale for thinking that by maintaining the structureincreased levels or activity of MsrA might retard the rate of aging. Indeed, transgenic Drosophila (fruit flies) that overexpress methionine sulfoxide reductase show extended lifespan. However, the effects of MsrA overexpression in mice were ambiguous. MsrA is found in both the cytosol and the energy-producing mitochondria, where most of the body's endogenous free radicals are produced. Transgenically increasing the levels of MsrA in either the cytosol or the mitochondria had no significant effect on lifespan assessed by most standard statistical tests, and may possibly have led to early deaths in the cytosol-specific mice, although the survival curves appeared to suggest a slight increase in maximum (90%) survivorship, as did analysis using Boschloo's test, a binomial test designed to test greater extreme variation. Deletion of this gene has been associated with insulin resistance in mice, while overexpression reduces insulin resistance in old mice.
First Minister of Wales Eluned Morgan is appointed a Privy Councillor. 29 August – Starmer confirms that the UK government is considering introducing tougher measures on outdoor smoking in order to reduce the number of tobacco-related deaths. Colum Eastwood announces he will resign as leader of the Social Democratic and Labour Party, triggering a leadership election. 30 August – A review is launched into Starmer's appointments of Labour donors to senior civil service jobs following allegations of cronyism. Conservative MP Esther McVey is criticised as "repugnant" by Jewish groups for sharing part of "First They Came", Martin Niemoller's 1946 poem about the Holocaust, in a tweet voicing her opposition to proposed new bans on outdoor smoking. McVey insists she was not equating the bans with Nazi persecution of the Jews, and says "no offence was ever intended". It is reported that Starmer has moved a portrait of Margaret Thatcher from her former 10 Downing Street study to elsewhere in the building. He subsequently says that he moved the portrait because he "didn’t want a picture of anyone" in his study and prefers landscapes. 2024 Ulster Unionist Party leadership election: After nominations close, Mike Nesbitt is the only candidate to put their name forward, and will be ratified as the party's next leader at a meeting on 14 September. During a closed-door session at the SNP Party Conference, leader John Swinney tells delegates the party's losses at the election occurred because it spent too much time focusing on the "process of independence".
Sources: en.wikipedia.org
The chemistry of plutonium was found to resemble uranium after a few months of initial study. Early research was continued at the secret Metallurgical Laboratory of the University of Chicago. On August 20, 1942, a trace quantity of this element was isolated and measured for the first time. About 50 micrograms of plutonium-239 combined with uranium and fission products was produced and only about 1 microgram was isolated. This procedure enabled chemists to determine the new element's atomic weight. On December 2, 1942, on a racket court under the west grandstand at the University of Chicago's Stagg Field, researchers headed by Enrico Fermi achieved the first self-sustaining chain reaction in a graphite and uranium pile known as CP-1. Using theoretical information garnered from the operation of CP-1, DuPont constructed an air-cooled experimental production reactor, known as X-10, and a pilot chemical separation facility at Oak Ridge. The separation facility, using methods developed by Glenn T. Seaborg and a team of researchers at the Met Lab, removed plutonium from uranium irradiated in the X-10 reactor. Information from CP-1 was also useful to Met Lab scientists designing the water-cooled plutonium production reactors for Hanford. Construction at the site began in mid-1943. In November 1943 some plutonium trifluoride was reduced to create the first sample of plutonium metal: a few micrograms of metallic beads. Enough plutonium was produced to make it the first synthetically made element to be visible with the unaided eye.
== 19th century: the emergence of biological disciplines == Up through the 19th century, the scope of biology was largely divided between medicine, which investigated questions of form and function (i.e., physiology), and natural history, which was concerned with the diversity of life and interactions among different forms of life and between life and non-life. By 1900, much of these domains overlapped, while natural history (and its counterpart natural philosophy) had largely given way to more specialized scientific disciplines—cytology, bacteriology, morphology, embryology, geography, and geology.
==== Health claims ==== The Japanese Ministry of Health, Labor, and Welfare (MHLW) set up the 'Foods for Specified Health Uses' (特定保健用食品; FOSHU) regulatory system in 1991 to individually approve the statements made on food labels concerning the effects of foods on the human body. The regulatory range of FOSHU was later broadened to allow for the certification of capsules and tablets. In 2001, MHLW enacted a new regulatory system, 'Foods with Health Claims' (保健機能食品; FHC), which consists of the existing FOSHU system and the newly established 'Foods with Nutrient Function Claims' (栄養機能表示食品; FNFC), under which claims were approved for any product containing a specified amount per serving of 12 vitamins, including vitamin B6, and two minerals. To make a health claim based on a food's vitamin B6 content, the amount per serving must be in the range of 0.3–25 mg. The allowed claim is: "Vitamin B6 is a nutrient that helps produce energy from protein and helps maintain healthy skin and mucous membranes." In 2010, the European Food Safety Authority (EFSA) published a review of proposed health claims for vitamin B6, disallowing claims for bone, teeth, hair skin and nails, and allowing claims that the vitamin provided for normal homocysteine metabolism, normal energy-yielding metabolism, normal psychological function, reduced tiredness and fatigue, and provided for normal cysteine synthesis. The US Food and Drug Administration (FDA) has several processes for permitting health claims on food and dietary supplement labels.
=== Binding assays === Polyhistidine-tagging can be used to detect protein-protein interactions in the same way as a pull-down assay. Polyhistidine tagging has several advantages over other tags commonly used for pull-down assays, including its small size, high binding capacity of the resin, few naturally occurring proteins binding to the carrier matrices and the increased stability of the carrier matrix over monoclonal antibody matrices.
Sources: en.wikipedia.org
== Other uses == Kombucha culture, when dried, becomes a leather-like textile known as a microbial cellulose that can be molded onto forms to create seamless clothing. Using different broth media such as coffee, black tea, and green tea to grow the kombucha culture results in different textile colors, although the textile can also be dyed using other plant-based dyes. Different growth media and dyes also change the textile's feel and texture. Dried and processed SCOBY has been investigated as a leather substitute. Additionally, the SCOBY itself can be dried and eaten as a sweet or savory snack. Kombucha can be further used for bioleaching of yttrium oxide from waste fluorescent lamp phosphors.
== Etymology == The word "soy" derives from the Japanese soi, a Kagoshima dialect variant of shōyu, which in turn comes from the Chinese jiangyou (醬油), meaning "soy sauce". The name of the genus, Glycine, comes from Linnaeus. When naming the genus, Linnaeus observed that one of the species formerly within the genus, which has since been reclassified to the genus Apios, had a sweet root. Based on the sweetness, the Greek word for sweet, glykós, was Latinized.
butyl The alkyl functional group derived from either of the two isomers of butane, with the generic chemical formula –C4H9. It may occur as a substituent in organic compounds or exist independently as an ion or radical. In IUPAC nomenclature, the presence of a butyl substituent is indicated with the prefix butyl in the name of the compound, or with the abbreviation Bu in chemical formulae; e.g. butyl alcohol (butanol), which may occur in any of five different isomeric forms depending on the arrangement of the four carbon atoms, is often written with the generic formula CH4CH9OH or BuOH.
Sources: en.wikipedia.org
TB-500 is a synthetic heptapeptide corresponding to a fragment of thymosin beta-4. It is used in laboratory research and is not an approved drug.
No. Thymosin beta-4 is a 43-amino-acid protein, while TB-500 represents only a short N-terminal segment. The two should not be treated as interchangeable in experimental design.
It is often called a thymosin beta-4 fragment, Tβ4 fragment, or Ac-LKKTETQ. The name TB-500 is mainly a commercial or catalog label rather than a formal chemical name.
No. TB-500 is a short synthetic peptide matching residues 17 to 23 of thymosin beta-4, while the parent protein contains 43 residues. The fragment lacks the rest of the protein sequence, so the two are related but not identical.